CTBP1 and neoplasm: Many studies showed the overexpression of β-ARs across multiple cancer types and the pharmacological inhibition of the β-ARs with beta blockers as anticancer agents supported the evidence that β-blockers contribute to improved survival and decrease tumour proliferation and progression in multiple cancer types [26,27,28].